Weekly paclitaxel plus estramustine combination therapy in hormone‐refractory prostate cancer: A pilot study

Background: Paclitaxel used in combination with estramustine has been shown to exert synergistic cytotoxicity in patients with hormone‐refractory prostate cancer (HRPC). There have been few reports of this therapy in an Asian male population.

[1]  K. Shigeno,et al.  Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. , 2002, The Journal of urology.

[2]  M. Zahurak,et al.  Phase II evaluation of docetaxel plus one‐day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma , 2002, Cancer.

[3]  K. Yamaguchi.  Overview of cancer control programs in Japan. , 2002, Japanese journal of clinical oncology.

[4]  K. Ushijima,et al.  Weekly 1 hour paclitaxel infusion in patients with recurrent gynecological tumors: a pilot study. , 2001, Japanese journal of clinical oncology.

[5]  G. Hudes,et al.  Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. , 2001, Urology.

[6]  B. Redman,et al.  Weekly 1‐hour infusion of paclitaxel , 2000, Cancer.

[7]  W. Oh.  Chemotherapy for patients with advanced prostate carcinoma , 2000, Cancer.

[8]  D. Petrylak,et al.  Chemotherapy for advanced hormone refractory prostate cancer. , 1999, Urology.

[9]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Budman,et al.  Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer. , 1999, Seminars in oncology.

[11]  C. Hudis,et al.  Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Litwin,et al.  Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Ozols,et al.  Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  D. Strumberg,et al.  Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. , 1996, European journal of cancer.

[15]  G. Hudes,et al.  Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. , 1995, Seminars in oncology.

[16]  M. Egorin,et al.  Paclitaxel pharmacokinetics and pharmacodynamics. , 1995, Seminars in oncology.

[17]  B. Yeap,et al.  Taxol in advanced, hormone‐refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group , 1993, Cancer.

[18]  B. Dahllöf,et al.  Estramustine depolymerizes microtubules by binding to tubulin. , 1993, Cancer research.

[19]  K. Tew,et al.  Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. , 1992, Cancer research.

[20]  S. Vogelgesang,et al.  Hypocalcemia associated with estrogen therapy for metastatic adenocarcinoma of the prostate. , 1988, The Journal of urology.

[21]  D. Citrin,et al.  Estramustine affects bone mineral metabolism in metastatic prostate cancer , 1986, Cancer.

[22]  C. Coleman,et al.  Clinical radiosensitization: why it does and does not work. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. Choy,et al.  Phase I trial of weekly paclitaxel in advanced lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Norton,et al.  Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  B R Goldspiel,et al.  Paclitaxel (Taxol) , 1994, Pharmacotherapy.